oxidopamine has been researched along with Central Nervous System Neoplasm in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Schlachetzki, F | 1 |
| Zhang, YF | 1 |
| Boado, RJ | 1 |
| Pardridge, WM | 1 |
1 other study available for oxidopamine and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter.
Topics: Animals; Antibodies, Monoclonal; Blood-Brain Barrier; Cell Nucleus; Central Nervous System Neoplasms | 2004 |